Alan Ashworth
#53,967
Most Influential Person Now
British biochemist
Alan Ashworth's AcademicInfluence.com Rankings
Alan Ashworthbiology Degrees
Biology
#2413
World Rank
#3831
Historical Rank
Biochemistry
#293
World Rank
#358
Historical Rank
Download Badge
Biology
Why Is Alan Ashworth Influential?
(Suggest an Edit or Addition)According to Wikipedia, Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research in London.
Alan Ashworth's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (2005) (5643)
- Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. (2009) (3354)
- A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing (2020) (3012)
- Identification of the breast cancer susceptibility gene BRCA2 (1995) (2451)
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. (2015) (1670)
- Hallmarks of 'BRCAness' in sporadic cancers (2004) (1593)
- PARP inhibitors: Synthetic lethality in the clinic (2017) (1491)
- Identification of the breast cancer susceptibility gene BRCA2 (1996) (1451)
- The DNA damage response and cancer therapy (2012) (1420)
- Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. (2006) (1221)
- An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1 (1995) (1214)
- Large-scale genotyping identifies 41 new loci associated with breast cancer risk (2013) (1063)
- The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus (1992) (965)
- Resistance to therapy caused by intragenic deletion in BRCA2 (2008) (933)
- CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members (2003) (931)
- Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. (2010) (931)
- BRCAness revisited (2016) (848)
- A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. (2008) (808)
- 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase (1997) (735)
- BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. (2010) (698)
- Identification of the familial cylindromatosis tumour-suppressor gene (2000) (683)
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (2009) (636)
- FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. (2010) (631)
- BRCA1 dysfunction in sporadic basal-like breast cancer (2007) (609)
- Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome (1991) (605)
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (587)
- The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability (2006) (584)
- Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction (2005) (571)
- Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. (1996) (561)
- MicroRNA Related Polymorphisms and Breast Cancer Risk (2014) (557)
- Identification of the sites in MAP kinase kinase‐1 phosphorylated by p74raf‐1. (1994) (539)
- Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
- Reprogramming human T cell function and specificity with non-viral genome targeting (2017) (503)
- Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer (2015) (502)
- Germline mutations in RAD51D confer susceptibility to ovarian cancer (2011) (493)
- Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants (2015) (471)
- The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families (1995) (461)
- A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing (2020) (456)
- Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences (2001) (434)
- Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation (1997) (431)
- Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
- Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. (2015) (402)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (398)
- Genetic Interactions in Cancer Progression and Treatment (2011) (397)
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency (2013) (392)
- BRCA2 mutations in primary breast and ovarian cancers (1996) (390)
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets (2009) (385)
- Stem cells and breast cancer: A field in transit (2003) (380)
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers (2013) (378)
- The Dual Specificity Phosphatases M3/6 and MKP-3 Are Highly Selective for Inactivation of Distinct Mitogen-activated Protein Kinases* (1996) (378)
- Expression of Xist during mouse development suggests a role in the initiation of X chromosome inactivation (1993) (365)
- Breast cancer molecular profiling with single sample predictors: a retrospective analysis. (2010) (362)
- CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells (2005) (344)
- Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland (2007) (340)
- MAP kinase phosphatases (2002) (334)
- Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification (1999) (330)
- Translating cancer research into targeted therapeutics (2010) (322)
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor (2008) (318)
- Functional and molecular characterisation of mammary side population cells (2002) (316)
- Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma (2011) (305)
- The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. (2002) (299)
- Basal-like breast carcinomas: clinical outcome and response to chemotherapy (2006) (297)
- Targeted therapy for cancer using PARP inhibitors. (2008) (292)
- Genome-wide association analysis identifies three new breast cancer susceptibility loci (2012) (291)
- Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor (2013) (291)
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (288)
- Identification of six Tcp-1-related genes encoding divergent subunits of the TCP-1-containing chaperonin (1994) (285)
- Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) (282)
- FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas (2006) (280)
- The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. (2008) (275)
- Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. (2014) (272)
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance (2017) (272)
- Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. (2013) (265)
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? (2018) (264)
- Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. (2011) (263)
- Xist has properties of the X-chromosome inactivation centre (1997) (259)
- Utilizing RNA interference to enhance cancer drug discovery (2007) (258)
- Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. (2004) (254)
- Emerging therapeutic targets in endometrial cancer (2011) (254)
- Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. (2012) (249)
- An SRY‐related gene expressed during spermatogenesis in the mouse encodes a sequence‐specific DNA‐binding protein. (1992) (247)
- A subset of ATM‐ and ATR‐dependent phosphorylation events requires the BRCA1 protein (2003) (246)
- Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. (2012) (244)
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors (2010) (243)
- Tankyrase-targeted therapeutics: expanding opportunities in the PARP family (2012) (242)
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A (2016) (239)
- EGFR amplification and lack of activating mutations in metaplastic breast carcinomas (2006) (235)
- Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. (2004) (227)
- Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis (2007) (227)
- Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. (2013) (225)
- Analysis of PALB2/FANCN-associated breast cancer families (2007) (219)
- Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. (2006) (218)
- Pregnancy and the risk of breast cancer. (2007) (218)
- Synthetic lethality as an engine for cancer drug target discovery (2019) (216)
- Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer (2012) (213)
- Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C (2014) (213)
- Marked for death: targeting epigenetic changes in cancer (2017) (210)
- Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis (2009) (207)
- Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. (2008) (205)
- Mismatch repair deficient colorectal cancer in the era of personalized treatment (2010) (203)
- Interaction between the Product of the Breast Cancer Susceptibility Gene BRCA2 and DSS1, a Protein Functionally Conserved from Yeast to Mammals (1999) (195)
- A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3) (2010) (194)
- DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1 (2010) (193)
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. (2017) (191)
- The BRC repeats are conserved in mammalian BRCA2 proteins. (1997) (188)
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer (2019) (183)
- Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas (2010) (183)
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. (2008) (181)
- Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers (2009) (181)
- Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity (2005) (181)
- p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene (2006) (179)
- DNA repair deficiency as a therapeutic target in cancer. (2008) (177)
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
- An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers (2010) (173)
- Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. (2005) (172)
- Familial non-specific dementia maps to chromosome 3. (1995) (172)
- Mammalian spermatogenic gene expression (1987) (170)
- Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations (2011) (170)
- Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. (1995) (169)
- Targeting the DNA repair defect of BRCA tumours. (2005) (168)
- FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo (2011) (164)
- Family history and risk of breast cancer: an analysis accounting for family structure (2017) (163)
- Whole genome sequencing of matched primary and metastatic acral melanomas. (2012) (161)
- Molecular Cloning and Functional Characterization of a Novel Mitogen-activated Protein Kinase Phosphatase, MKP-4* (1997) (160)
- Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 (2009) (160)
- LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest (2010) (159)
- Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR (2013) (157)
- BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency (2005) (155)
- Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. (2012) (154)
- Towards high resolution maps of the mouse and human genomes--a facility for ordering markers to 0.1 cM resolution. European Backcross Collaborative Group. (1994) (154)
- HEX: a novel homeobox gene expressed during haematopoiesis and conserved between mouse and human. (1993) (154)
- PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas (2009) (153)
- Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas (2008) (153)
- Therapeutic Targeting of the DNA Mismatch Repair Pathway (2010) (152)
- Structural basis for recruitment of BRCA2 by PALB2 (2009) (151)
- Functional viability profiles of breast cancer. (2011) (151)
- A conserved family of genes related to the testis determining gene, SRY. (1992) (150)
- The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study. (2014) (150)
- Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor. (2000) (149)
- A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity (2013) (148)
- A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas (2010) (148)
- PARP inhibitor combination therapy. (2016) (148)
- MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases (1999) (147)
- The Sry-related HMG box-containing gene Sox6 is expressed in the adult testis and developing nervous system of the mouse. (1995) (144)
- Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines (2008) (144)
- Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. (2005) (144)
- Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type (2010) (143)
- A mouse model of basal‐like breast carcinoma with metaplastic elements (2007) (140)
- Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast (2008) (139)
- Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. (2003) (137)
- DNA binding and bending properties of the post-meiotically expressed Sry-related protein Sox-5. (1994) (137)
- Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data (2006) (136)
- Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement (2011) (136)
- Microarray and histopathological analysis of tumours: the future and the past? (2001) (134)
- Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas (2009) (132)
- Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors (2015) (130)
- X-chromosome inactivation may explain the difference in viability of XO humans and mice (1991) (129)
- Molecular response to aromatase inhibitor treatment in primary breast cancer (2007) (129)
- Gene expression following ionising radiation: Identification of biomarkers for dose estimation and prediction of individual response (2011) (127)
- Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
- Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets (2009) (125)
- Mechanisms of Disease: angiogenesis and the management of breast cancer (2007) (124)
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer (2011) (124)
- Correction: Functional and molecular characterisation of mammary side population cells (2002) (124)
- Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen (2011) (124)
- Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse (2006) (124)
- Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas (2011) (123)
- DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells (2004) (123)
- New complexities for BRCA1 and BRCA2 (2001) (123)
- High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing (2011) (123)
- Challenges translating breast cancer gene signatures into the clinic (2012) (122)
- Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. (2007) (121)
- Determinants of age at menarche in the UK: analyses from the Breakthrough Generations Study (2010) (121)
- Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study (2013) (118)
- A candidate spermatogenesis gene on the mouse Y chromosome is homologous to ubiquitin-activating enzyme E1 (1991) (118)
- Functions of the BRCA1 and BRCA2 genes. (1998) (117)
- Zfa is an expressed retroposon derived from an alternative transcript of the Zfx gene. (1990) (116)
- 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. (2012) (115)
- Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. (2020) (115)
- Nuclear location and cell cycle regulation of the BRCA2 protein. (1997) (115)
- Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study (2014) (114)
- Smoking and risk of breast cancer in the Generations Study cohort (2017) (114)
- Making the best of PARP inhibitors in ovarian cancer (2010) (112)
- Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2014) (112)
- Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. (2013) (109)
- Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. (2013) (108)
- Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. (2006) (108)
- Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. (2015) (107)
- Regulation of the Wnt signalling component PAR1A by the Peutz–Jeghers syndrome kinase LKB1 (2003) (107)
- Drug resistance caused by reversion mutation. (2008) (107)
- The cancer cell map initiative: defining the hallmark networks of cancer. (2015) (105)
- Evolutionary rate of a gene affected by chromosomal position (1999) (104)
- Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells (2012) (103)
- Synthetic lethal approaches to breast cancer therapy (2010) (102)
- Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment (2006) (101)
- The potential of exploiting DNA-repair defects for optimizing lung cancer treatment (2012) (101)
- Molecular profiling of breast cancer: clinical implications (2004) (100)
- A genome-wide association study of early menopause and the combined impact of identified variants (2013) (99)
- LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1. (2001) (99)
- Searching for synthetic lethality in cancer. (2011) (98)
- DNA methylation landscapes in advanced prostate cancer (2020) (98)
- Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance (2006) (97)
- Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis (2015) (96)
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast (2014) (96)
- Secular trends in age at menarche in women in the UK born 1908-93: results from the Breakthrough Generations Study. (2011) (96)
- The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase. (1999) (93)
- Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines (2016) (92)
- Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy (2006) (92)
- A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake (2003) (92)
- Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue (2006) (91)
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. (2015) (91)
- The Breakthrough Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology (2011) (91)
- Body mass index, exercise, and other lifestyle factors in relation to age at natural menopause: analyses from the breakthrough generations study. (2012) (91)
- Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. (2011) (90)
- Expression of sox11 gene duplicates in zebrafish suggests the reciprocal loss of ancestral gene expression patterns in development (2000) (90)
- A novel short splice variant of the tumour suppressor LKB1 is required for spermiogenesis. (2008) (90)
- Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? (2009) (89)
- Familial concordance for age at menarche: analyses from the Breakthrough Generations Study. (2011) (87)
- Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation (2012) (87)
- The genomic profile of HER2‐amplified breast cancers: the influence of ER status (2008) (87)
- An expanded universe of cancer targets (2021) (86)
- Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization (2006) (86)
- A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D (2008) (86)
- Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. (2015) (86)
- Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study (2005) (85)
- Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. (2011) (84)
- LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells (2009) (82)
- LKB1 is required for hepatic bile acid transport and canalicular membrane integrity in mice (2010) (81)
- A role for JNK/SAPK in proliferation, but not apoptosis, of IL-3-dependent cells (1997) (80)
- BRCA1 and BRCA2 (2000) (79)
- Lkb1 deficiency causes prostate neoplasia in the mouse. (2008) (78)
- Genomic instability and the selection of treatments for cancer (2009) (77)
- The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis (2006) (76)
- Cloning and characterization of SOX5, a new member of the human SOX gene family. (1996) (76)
- A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines (2009) (75)
- Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components (2009) (75)
- The Y* rearrangement in mice: new insights into a perplexing PAR (1998) (75)
- Signalling Pathways Implicated in Early Mammary Gland Morphogenesis and Breast Cancer (2006) (75)
- Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib (2016) (74)
- ADP-ribosyltransferases, an update on function and nomenclature (2021) (74)
- Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification. (2005) (74)
- An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. (2014) (73)
- Transgenic mice carrying an Xist-containing YAC. (1996) (72)
- A gene spans the pseudoautosomal boundary in mice. (1997) (72)
- A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer (2013) (71)
- Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency (2013) (71)
- Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells (2017) (70)
- CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2016) (70)
- APRIN is a cell cycle specific BRCA2‐interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer (2012) (70)
- Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer (2009) (68)
- E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. (2018) (68)
- Lkb1 Deficiency Alters Goblet and Paneth Cell Differentiation in the Small Intestine (2009) (68)
- Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA (2018) (67)
- PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study (2010) (65)
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib (2012) (65)
- Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour (2007) (65)
- Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. (2013) (65)
- A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
- Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry (2018) (64)
- Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation (2007) (64)
- Complementation of byrl in fission yeast by mammalian MAP kinase kinase requires coexpression of Raf kinase (1993) (64)
- Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. (1997) (64)
- LKB1 Kinase: Master and Commander of Metabolism and Polarity (2004) (63)
- Identification of miRNA modulators to PARP inhibitor response. (2013) (63)
- Common genetic variants are significant risk factors for early menopause: results from the Breakthrough Generations Study (2010) (63)
- Targeting p90 Ribosomal S6 Kinase Eliminates Tumor‐Initiating Cells by Inactivating Y‐Box Binding Protein‐1 in Triple‐Negative Breast Cancers (2012) (63)
- Association of Genetic Variants at 8q24 with Breast Cancer Risk (2008) (63)
- Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. (2006) (63)
- Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? (2016) (62)
- Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium (2014) (62)
- Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress (2014) (62)
- BRCA1 and BRCA2 as ovarian cancer susceptibility genes. (2005) (62)
- Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk. (1995) (62)
- Genome-wide association study identifies a novel variant in RAD51B associated with male breast cancer risk (2012) (61)
- Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. (2009) (61)
- Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition (2010) (61)
- Receptor and secreted targets of Wnt-1/β-catenin signalling in mouse mammary epithelial cells (2005) (61)
- Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (60)
- The proteasome is involved in determining differential utilization of double-strand break repair pathways (2007) (60)
- Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation (2002) (60)
- HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer (2020) (60)
- The amino acid sequence of a mammalian MAP kinase kinase. (1992) (60)
- Molecular Genetic Characterisation of Frontotemporal Dementia on Chromosome 3 (1999) (58)
- Familial concordance for age at natural menopause: results from the Breakthrough Generations Study (2011) (58)
- Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer (2019) (57)
- Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor (2012) (57)
- Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 Controls (2009) (57)
- Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study (2014) (56)
- Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells (2009) (55)
- Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumor (2011) (55)
- Structural analysis of the chicken BRCA2 gene facilitates identification of functional domains and disease causing mutations. (2002) (54)
- Modeling Therapy Resistance in BRCA1/2-Mutant Cancers (2017) (54)
- Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours (2011) (53)
- Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom (2016) (53)
- Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia (1996) (52)
- Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy (2006) (52)
- The ZFY gene family in humans and mice. (1991) (52)
- Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking (2021) (52)
- Cloning of a potentially soluble receptor for human GM-CSF. (1990) (52)
- Control of aromatase in breast cancer cells and its importance for tumor growth (1993) (52)
- A contravention of Ohno's law in mice (1995) (52)
- Deletion of Lkb1 in Pro-Opiomelanocortin Neurons Impairs Peripheral Glucose Homeostasis in Mice (2011) (52)
- Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. (2015) (51)
- Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation (2010) (51)
- Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways (2015) (50)
- Biology-driven cancer drug development: back to the future (2010) (50)
- Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast (2010) (50)
- Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 (2015) (50)
- The genomic landscape of oesophagogastric junctional adenocarcinoma (2013) (49)
- Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast (2014) (49)
- RAD51, BRCA2 and DNA repair: a partial resolution (2007) (49)
- Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039)) (2018) (48)
- A zinc finger protein-encoding gene expressed in the post-meiotic phase of spermatogenesis. (1991) (48)
- Inherited cylindromas: lessons from a rare tumour. (2015) (48)
- A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers (2019) (48)
- Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. (2008) (48)
- Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma (2009) (48)
- Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer (2015) (47)
- Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers (2014) (46)
- Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication (2009) (46)
- Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. (2009) (46)
- A member of the MAP kinase phosphatase gene family in mouse containing a complex trinucleotide repeat in the coding region. (1996) (46)
- Isolation and sequence of a human cytochrome P-450 cDNA clone. (1985) (45)
- Genetic Variants at Chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 Influence the Risk of Breast Cancer in Men (2011) (45)
- Sequence of cDNA for murine Zfy-1, a candidate for Tdy. (1989) (45)
- Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation (2009) (45)
- The DNA methylation landscape of advanced prostate cancer (2020) (44)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (44)
- Isolation of a human cytochrome P‐450 reductase cDNA clone and localization of the corresponding gene to chromosome 7q11.2 (1989) (43)
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing (2020) (43)
- Genomic characterisation of acral melanoma cell lines (2012) (43)
- Multiple Hodgkin lymphoma-associated loci within the HLA region at chromosome 6p21.3. (2011) (41)
- Neuregulin3 alters cell fate in the epidermis and mammary gland (2007) (40)
- Brca2 and Trp53 Deficiency Cooperate in the Progression of Mouse Prostate Tumourigenesis (2010) (40)
- A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. (2014) (40)
- Cloning, chromosomal localization and expression pattern of the POU domain gene Oct-11 (1993) (39)
- Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines (2011) (39)
- Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells. (1994) (38)
- 11q13 is a susceptibility locus for hormone receptor positive breast cancer (2012) (38)
- Phenotypic effects of heterozygosity for a BRCA2 mutation. (2003) (38)
- Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls (2010) (38)
- High-throughput RNAi screening reveals novel regulators of telomerase. (2011) (37)
- Differential effects of stress stimuli on a JNK-inactivating phosphatase (2002) (37)
- Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence (2022) (37)
- Genome‐wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c‐Kit, CD117) and oestrogen receptor‐α (ERα) in response to therapeutic radiation (2009) (37)
- ATR Is a Therapeutic Target in Synovial Sarcoma. (2017) (37)
- The promise of combining inhibition of PI3K and PARP as cancer therapy. (2012) (37)
- A member of the caudal family of homeobox genes maps to the X-inactivation centre region of the mouse and human X chromosomes. (1995) (36)
- LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. (2007) (36)
- Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer. (2015) (35)
- Functional characterization of EMSY gene amplification in human cancers (2011) (35)
- Functional and molecular characterisation of mammary side population cells (vol 5, pg R1, 2003) (2003) (35)
- Investigation of gene‐environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors (2015) (35)
- A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors (2019) (35)
- Functional analysis of Drosophila melanogaster BRCA2 in DNA repair. (2008) (34)
- FXY2/MID2, a gene related to the X-linked Opitz syndrome gene FXY/MID1, maps to Xq22 and encodes a FNIII domain-containing protein that associates with microtubules. (1999) (34)
- Structure and expression of the gene encoding mouse t-complex polypeptide (Tcp-1). (1992) (34)
- Overexpression of MYB drives proliferation of CYLD‐defective cylindroma cells† (2016) (34)
- Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. (2015) (34)
- Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study (2018) (33)
- Chromosomal localization of zinc finger protein genes in man and mouse. (1989) (33)
- Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions (2014) (33)
- Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress (2013) (32)
- JNK activation is not required for Fas-mediated apoptosis (1999) (32)
- An integrated molecular profile of endometrioid ovarian cancer. (2020) (32)
- Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (31)
- Biomarkers of PARP inhibitor sensitivity (2011) (31)
- Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers (2007) (31)
- The San Francisco Cancer Initiative: A Community Effort To Reduce The Population Burden Of Cancer. (2018) (31)
- CYP3A variation, premenopausal estrone levels, and breast cancer risk. (2012) (31)
- Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking (2020) (31)
- Structural basis for recruitment of BRCA2 by PALB2 (2017) (31)
- Dynamic expression of Erbb pathway members during early mammary gland morphogenesis. (2008) (30)
- Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells (2006) (30)
- Chromosomal localization of three human dual specificity phosphatase genes (DUSP4, DUSP6, and DUSP7). (1997) (30)
- AXL and acquired resistance to EGFR inhibitors (2012) (29)
- DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. (2016) (29)
- Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity (2003) (29)
- An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer (2013) (29)
- Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study (2014) (28)
- Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies (2014) (28)
- A protein interaction landscape of breast cancer (2021) (28)
- Cloning and sequence analysis of a rat liver cDNA coding for a phenobarbital-inducible microheterogenous cytochrome P-450 variant: regulation of its messenger level by xenobiotics. (1983) (28)
- Structural variation of the pseudoautosomal region between and within inbred mouse strains. (1996) (28)
- Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking (2020) (27)
- Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. (2016) (27)
- A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (27)
- Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors (2008) (27)
- Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. (2014) (26)
- The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling (2014) (26)
- X-linked microtubule-associated protein, Mid1, regulates axon development (2013) (26)
- Transition from cylindroma to spiradenoma in CYLD‐defective tumours is associated with reduced DKK2 expression (2011) (26)
- PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017) (25)
- Can genetic testing guide treatment in breast cancer? (2008) (25)
- Profiling familial breast cancer (2001) (25)
- Changes in estradiol and testosterone levels in postmenopausal women after changes in body mass index. (2013) (25)
- Therapeutic potential of PARP inhibitors for metastatic breast cancer (2011) (24)
- FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. (2012) (24)
- Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase (2013) (24)
- 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium (2012) (24)
- Klotho: A Major Shareholder in Vascular Aging Enterprises (2019) (24)
- RNA interference screening demystified (2009) (23)
- Intestinal renin–angiotensin system is stimulated after deletion of Lkb1 (2011) (23)
- A Modified Method for Whole Exome Resequencing from Minimal Amounts of Starting DNA (2012) (23)
- BRCA1 and stem cells: tumour typecasting (2008) (23)
- BRCA1 and BRCA2 bind Stat5a and suppress its transcriptional activity (2002) (23)
- Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. (2013) (23)
- Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine‐tiling oligonucleotide array CGH (2007) (23)
- An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells (1995) (23)
- An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence (2011) (22)
- FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium (2014) (22)
- CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. (2009) (22)
- The human FXY gene is located within Xp22.3: implications for evolution of the mammalian X chromosome. (1998) (22)
- ESR1 gene amplification in breast cancer: a common phenomenon? (2008) (22)
- DNA amplifications in breast cancer: genotypic-phenotypic correlations. (2010) (22)
- The pathology of familial breast cancer: The pathology of familial breast cancer How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology? (1999) (22)
- Male breast cancer, age and sex chromosome aneuploidy (2013) (21)
- DAISY: picking synthetic lethals from cancer genomes. (2014) (21)
- NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells (2012) (21)
- Comprehensive Genomic Analysis of a BRCA2 Deficient Human Pancreatic Cancer (2011) (21)
- RASA2 ablation in T cells boosts antigen sensitivity and long-term function (2022) (20)
- Effect of Delays in Processing Blood Samples on Measured Endogenous Plasma Sex Hormone Levels in Women (2007) (20)
- D-Day for BRCA2 (2002) (20)
- Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. (2008) (20)
- Array CGH of fusion gene–positive leukemia‐derived cell lines reveals cryptic regions of genomic gain and loss (2006) (19)
- Inhibition of aromatase expression by a psoralen‐linked triplex‐forming oligonucleotide targeted to a coding sequence (1995) (19)
- Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer (2017) (19)
- sox30: a novel zebrafish sox gene expressed in a restricted manner at the midbrain-hindbrain boundary during neurogenesis (1999) (19)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Cloning and sequencing of POU-boxes expressed in mouse testis. (1990) (18)
- Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology (2012) (18)
- Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. (2019) (18)
- Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH (2005) (18)
- New biology of the oestrogen receptor (2003) (17)
- Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets (2018) (17)
- Childhood body size and pubertal timing in relation to adult mammographic density phenotype (2017) (17)
- IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma (2010) (17)
- Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity (2015) (17)
- DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade (2018) (16)
- Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor (2015) (16)
- Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia. (1996) (15)
- Whole‐exome DNA sequence analysis of Brca2‐ and Trp53‐deficient mouse mammary gland tumours (2015) (15)
- Alternative splicing of the Drosophila PTEN gene. (1999) (15)
- Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib (2018) (15)
- DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway (2019) (15)
- BRCA2 in meiosis: turning over a new leaf. (2004) (14)
- Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line (2002) (14)
- Bringing DNA Repair in Tumors into Focus (2009) (14)
- Using functional genetics to understand breast cancer biology. (2010) (14)
- Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. (2015) (14)
- Abstract S6-01:BRCA1methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) (2017) (14)
- p 53 modulates homologous recombination by transcriptional regulation of the RAD 51 gene (2013) (14)
- Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. (2014) (14)
- Linkage analysis of the fragile X gene FMR‐1 and schizophrenia: no evidence for linkage but report of a family with schizophrenia and an unstable triplet repeat (1996) (14)
- Two acetyl-CoA acetyltransferase genes located in the t-complex region of mouse chromosome 17 partially overlap the Tcp-1 and Tcp-1x genes. (1993) (13)
- LKB 1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells (2009) (13)
- Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation (2008) (13)
- Zfy1 encodes a nuclear sequence‐specific DNA binding protein (1995) (13)
- Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway (2015) (13)
- Klotho and the Treatment of Human Malignancies (2020) (13)
- Cancer predisposition: Where's the phosphate? (1998) (13)
- A missense mutation in the BRCA2 gene in three siblings with ovarian cancer. (1998) (13)
- X-Chromosome Inactivation: X Marks the Spot for BRCA1 (2003) (12)
- Patchy fur, a mouse coat mutation associated with X-Y nondisjunction, maps to the pseudoautosomal boundary region. (1998) (12)
- Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors (2015) (12)
- Oh what a tangled web it weaves: BRCA1 and DNA decatenation. (2005) (12)
- Reproducibility of estradiol and testosterone levels in postmenopausal women over 5 years: results from the breakthrough generations study. (2014) (12)
- Zinc finger protein genes in the mouse genome (2004) (12)
- Association of Genetic Variants at 8 q 24 with Breast Cancer Risk (2008) (11)
- Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells (2017) (11)
- An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer (2021) (11)
- Genomics: Comparisons across cancers (2013) (11)
- Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma* (2016) (11)
- Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (11)
- Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study (2018) (11)
- The mouse Ftzf1 gene required for gonadal and adrenal development maps to mouse chromosome 2. (1995) (11)
- An improved definition of mouse mammary epithelial side population cells. (2005) (10)
- Elevated APOBEC 3 B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p 53-defective cells (2017) (10)
- Familial concordance for height and its components: Analyses from the breakthrough generations study (2012) (10)
- Sequence of cDNA for Xenopus XZFY-1. (1992) (10)
- Common Susceptibility Loci for Male Breast Cancer (2020) (9)
- Autoantibody Landscape in Patients with Advanced Prostate Cancer (2020) (9)
- Tumor and Stem Cell Biology Cancer Research FGFR 1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer (2010) (9)
- Supplemental Data The Structure of the CYLD USP Domain Explains Its Specificity for Lys 63-Linked Polyubiquitin and Reveals a B Box Module (2008) (8)
- HIGH GRADE GLIOMAS (2012) (8)
- Disease gene relationship seen (1986) (8)
- Refocusing on BRCA1 (2004) (8)
- Isolation and characterization of genes coding for cytochrome b5 and cytochrome- b5 reductase (1989) (7)
- A new gene on the X involved in Fanconi anemia (2004) (7)
- The upstream region of the mouse Xist gene contains two ribosomal protein pseudogenes (2000) (6)
- Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2018) (6)
- A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models (2020) (6)
- Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial (2017) (6)
- The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and X-ray diffraction at room temperature (2022) (6)
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2 (2023) (6)
- Reply to J. Veeck et al (2010) (5)
- Construction of specific cosmids from YACs by homologous recombination in yeast. (1995) (5)
- Factors controlling the expression of genes coding for drug-metabolizing enzymes. (1983) (5)
- Structure and expression of genes coding for components of the cytochrome P-450-mediated mono-oxygenase. (1987) (5)
- Inherited Genetic Factors and Breast Cancer (2010) (5)
- Microheterogeneity in a cytochrome P-450 multigene family (1984) (5)
- From Cancer Epidemiology to Policy and Practice: the Role of a Comprehensive Cancer Center (2022) (4)
- ATR Inhibitors and Paclitaxel in Melanoma (2021) (4)
- Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2017) (4)
- The 5-Hydroxymethylcytosine Landscape of Prostate Cancer (2022) (4)
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2 (2022) (4)
- Structure and chromosomal mapping of the TNF-alpha inducible endothelial protein 1 (Edp1) gene in the mouse. (1998) (4)
- Determinants of age at menarche in the United Kingdom: analyses from the Breakthrough Generations Study (2010) (4)
- CYP 3 A Variation , Premenopausal Estrone Levels , and Breast Cancer Risk (2012) (4)
- Reply to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study” (2018) (4)
- Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice (2020) (4)
- The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature (2022) (4)
- Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (4)
- Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression (2022) (3)
- Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom (2016) (3)
- Pilot study demonstrating changes in DNA hydroxymethylation enable detection of multiple cancers in plasma cell-free DNA (2020) (3)
- Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2. (2009) (3)
- Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas. (2010) (3)
- Frontal lobe or `nonspecific' dementias are genetically heterogeneous (1995) (3)
- Reprogramming human T cell function and specificity with non-viral genome targeting (2018) (3)
- Dissecting resistance to endocrine therapy in breast cancer (2008) (3)
- Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study (2020) (3)
- Response to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study” (2018) (3)
- A DISTINCT SPECTRUM OF COPY NUMBER ABERRATIONS IN FORMALIN-FIXED, PARAFFIN-EMBEDDED PAEDIATRIC HIGH GRADE GLIOMA (2010) (3)
- Zfp 30, a KRAB domain containing zinc finger protein gene, maps to mouse chromosome 7 (1994) (2)
- Abstract 4045: Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk (2012) (2)
- Targeting mismatch repair deficiency Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH 2 (2009) (2)
- Correction: A Modified Method for Whole Exome Resequencing from Minimal Amounts of Starting DNA (2012) (2)
- Structure and expression of rat and human cytochrome P-450 genes (1985) (2)
- Correction: Lkb1 Deficiency Alters Goblet and Paneth Cell Differentiation in the Small Intestine (2009) (2)
- Zfyl encodes a nuclear sequence-specific DNA binding protein. (1995) (2)
- Close relatives or distant cousins? (2003) (2)
- Linkage mapping of murine homolog of the yeast SPT6 gene to MMU11B1 (2009) (2)
- Gene expression arrays for the prediction of response to doxorubicin and cyclophosphamide (AC) in human breast cancers (2005) (2)
- Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma. (2013) (2)
- Structure-based inhibitor optimization for the Nsp3 Macrodomain of SARS-CoV-2. (2022) (2)
- 5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC. (2021) (2)
- The Y* rearrangement in mice: new insights into a perplexing pseudoautosomal region (1998) (2)
- Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2018) (2)
- Abstract LB-060: A very long-acting poly(ADP-ribose) polymerase inhibitor (2020) (1)
- PD-0017DRUGGABLE GENETIC DEPENDENCIES FOR MOLECULARLY DEFINED SUBGROUPS OF OESOPHAGEAL CANCER IDENTIFIED FROM HIGH-THROUGHPUT FUNCTIONAL PROFILING (2014) (1)
- Structure and expression of genes coding for phenobarbital-inducible cytochromes P-450 (1984) (1)
- Abstract 350: High-throughput drug screens identify novel synthetic lethal interactions with MLH1-deficient cancers (2011) (1)
- Isolation and characterization of genes coding for cytochrome b, and cytochrome- b, reductase (1989) (1)
- Abstract S4-02: Integrated genomic analyses of members of protein kinase C family identifies subtype specific alterations as novel therapeutic targets (2013) (1)
- Roles of the BRCA1 and BRCA2 Breast Cancer Susceptibility Proteins in DNA Repair (2006) (1)
- Biomedicine. D-Day for BRCA2. (2002) (1)
- Unravelling cylindromas: insights into appendageal tumour patterning from patients with truncating CYLD mutations (2010) (1)
- Chemosensitivity proボling of osteosarcoma tumour cell lines identiボes a model of BRCAness (1)
- Dysregulated tropomyosin receptor kinase signalling in CYLDtrunc/trunc tumours (2010) (1)
- Correction: Timing of pubertal stages and breast cancer risk: The breakthrough generations study (Breast Cancer Research (2014) 16 (R18) DOI: 10.1186/bcr3613) (2020) (1)
- Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer (2011) (1)
- The importance of gene-centring microarray data – Authors' reply (2010) (1)
- Abstract 2962: Histone H3.3 mutations drive paediatric glioblastoma through upregulation of MYCN. (2013) (1)
- Developing rational drug combination strategies for PARP inhibitors. (2012) (1)
- Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer (2022) (1)
- Abstract 1372: Detection of early stage pancreatic cancer using 5–hydroxymethylcytosine signatures in circulating cell free DNA (2019) (1)
- A whole genome CRISPR screen identifies AHR loss as a mechanism of PARP7 inhibitor resistance. (2022) (1)
- Abstract 2743: Finding determinants of PARP inhibitor sensitivity using genome-wide and focused CRISPR screens (2016) (1)
- Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis (2015) (1)
- 147 An integrated approach for identifying E-cadherin synthetic lethality networks (2014) (1)
- Abstract PD05-08: Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification (2012) (1)
- Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (1)
- Predictive Biomarkers and Personalized Medicine A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (1)
- LAB-PEDIATRICS LABORATORY RESEARCH (2012) (1)
- PD05-06: Determination of HER2 Status with Analysis of Plasma DNA by Digital PCR in Patients with Metastatic Breast Cancer. (2011) (1)
- Abstract 1225: Rare variants in DNA damage repair genes are associated with male breast cancer predisposition (2018) (1)
- Familial breast cancer: the first linkage. (2009) (1)
- Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2016) (1)
- INTEGRATED WHOLE GENOME AND RNA SEQUENCING IDENTIFIES NOVEL EXPRESSED FUSION TRANSCRIPTS IN PAEDIATRIC HIGH GRADE GLIOMA (2013) (1)
- Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis association study reveals decreased average methylation levels years before breast cancer (2018) (1)
- BRCA2 in chronic lymphocytic leukemia Frequent somatic deletion of the 13q12.3 locus encompassing (2011) (1)
- Immunotherapeutic targeting and PET imaging of DLL3 in small cell neuroendocrine prostate cancer. (2022) (1)
- Validation of anti-correlated TGFβ signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy. (2022) (1)
- A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (1)
- A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors (2019) (1)
- An interview with Pharmacogenomics for the breast cancer special focus issue. (2012) (1)
- 343 Synthetic lethal approaches to cancer therapy (2010) (1)
- Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors (2023) (1)
- Tumour-Specific Synthetic Lethality: Targeting BRCA Dysfunction in Ovarian Cancer (2011) (1)
- Hemangioendothelioma Identification of a Disease-Defining Gene Fusion in Epithelioid (2011) (1)
- Issue Information (2018) (0)
- PL-01. IDENTIFICATION OF NOVEL FUSION GENES IN PEDIATRIC HIGH-GRADE GLIOMA (2012) (0)
- Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets (2018) (0)
- Abstract B24: Using KRAS synthetic lethality to design novel therapeutic approaches to cancer (2013) (0)
- 122 INVITED Tumour – Stroma Interactions in Breast Cancer Metastasis (2011) (0)
- P1-06-22: Identification of Biomarkers in Breast Cancer for Prediction of Response to PARP Inhibitor Olaparib. (2011) (0)
- Abstract A184: Integrative molecular and functional profiling of HER2 amplified breast cancers to identify new gene targets. (2011) (0)
- 105 Functional Profiling of Clear Cell Ovarian Cancer (2012) (0)
- An Inducible Cre Mouse with Preferential Activity in Vascular Smooth Muscle Evades a Previously Lethal Intestinal Phenotype (2022) (0)
- Fine-mapping identifies two additional susceptibility 9q31.2. (2015) (0)
- Combined aCGH and Mutational Analysis of CLL Patients with 17p Deletion. (2006) (0)
- Abstract P6-06-01: Analyzing the physical and functional protein interaction landscape of breast cancer (2019) (0)
- Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D (2020) (0)
- Invited Papers 2 (2004) (0)
- Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
- Abstract SY01-01: Harnessing genetic dependencies in cancer therapy (2011) (0)
- Emerging therapeutic targets in endometrial (2011) (0)
- PEPTIDE VACCINE THERAPY FOR CHILDHOOD GLIOMAS : INTERIM RESULTS OF A PILOT STUDY (0)
- CONTENTS (2006) (0)
- Abstract P5-05-02: Whole Genome In Vivo RNA Interference Screening Identifies the Leukemia Inhibitory Factor Receptor as a Novel Breast Tumor Suppressor (2010) (0)
- Design and Discovery of 3-Aryl-5-Substituted-Isoquinolin-1-Ones as Potent and Selective Tankyrase Inhibitors (2015) (0)
- G/T polymorphism in CRYA2 gene. (1994) (0)
- Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity (2013) (0)
- The importance of gene-centring microarray data Reply (2010) (0)
- MicroRNA related polymorphisms and breast cancer risk - eScholarship (2014) (0)
- Advances in the development of new therapies for CYLD mutation carriers Targeting Trk (2010) (0)
- Functional profiling of clear cell ovarian cancer. (2012) (0)
- Fanconi anaemia and breast cancer - what is the connection? (2003) (0)
- Scientist in residence 2012 (2012) (0)
- Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study (2020) (0)
- Materials and Methods with respect to the identification and sequencing of the BRCA2 cancer-suszeptilitaetsgens and its applications (1996) (0)
- Response to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study” (2018) (0)
- Table of Contents (1994) (0)
- 106 Identifying KRAS New Synthetic Lethality Relationships in Cancer (2012) (0)
- Abstract P5-02-01: FGFR Signalling Drives the Growth of Triple Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo (2010) (0)
- Abstract IA14: Harnessing genetic dependencies in cancer therapy (2013) (0)
- A new molecular target in colorectal cancer signalling: The LKB1 tumour suppressor gene and Wnt signalling (2004) (0)
- Bacterial Artificial Chromosome (BAC) Array CGH Study of B-CLL Patients with 17p13 Deletion. (2005) (0)
- Exploiting DNA damage repair defects for effective targeting of acute myeloid leukaemia by PARP inhibitors (2016) (0)
- Complete sequencing of the mouse pseudoautosomal region, the most rapidly evolving ‘chromosome’ (2022) (0)
- NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear–mitochondrial crosstalk in ERCC1-deficient populations (2016) (0)
- 10th Biennial Helene Harris Memorial Trust meeting. (2006) (0)
- Synthetic lethal targeting of oncogenic transcription factors in acute myeloid leukemia using PARP inhibitors (2015) (0)
- Mapping the Molecular Alterations In IGF-Driven Wilms Tumorigenesis – Perilobar Nephrogenic Rests as Non-Obligate Molecular Genetic Precursor Lesions (2008) (0)
- Cloning of cDNA coding for a rat liver protein whose expression is subject to gender-specific regulation by xenobiotics. (1984) (0)
- Abstract B201: Identification of miRNA modulators to PARP inhibitor response. (2011) (0)
- 108 Parallel siRNA and Compound Screens to Identify Molecular Determinants of Sensitivity to WEE1 Inhibition in Breast Cancer (2012) (0)
- Stage 2 Genome-Wide Association Study of Candidate Low Penetrance Genes Implicated in Breast Cancer Risk (2009) (0)
- New complexities for BRAC1 and BRAC2. (2001) (0)
- Abstract 617: High-throughput screens identify PARP inhibition as being synthetically lethal with ERCC1 deficiency in non-small cell lung cancer cell lines. (2013) (0)
- ATM intragenic methylation as a breast cancer risk marker-1-Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk (2012) (0)
- Abstract 69: Identification of new therapeutic targets and molecular predictors of response in oesophageal cancer (2016) (0)
- O8: Array CGH Using Whole Genome Amplification Of Fresh Frozen And Formalin-Fixed, Paraffin-Embedded Tumour DNA (2005) (0)
- Abstract 2426: Exacerbation of oxidative DNA damage as a synthetic lethal approach in mismatch repair deficient tumors (2014) (0)
- P43: Genomic changes in favourable histology Wilms tumours analysed by genome-wide 1 Mb-spaced and chromosome 1 tiling-path array CGH (2005) (0)
- Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas. (2010) (0)
- Identifying Modifiers of Tamoxifen Sensitivity Using High-Throughput Genetic and Chemical Screens (2009) (0)
- Association of rs12662670 with breast cancer in Asian ER (2012) (0)
- O18: Tiling path array CGH of breast cancer cell lines and integration with expression profiling (2005) (0)
- Reelin as a candidate gene for schizophrenia (2003) (0)
- Author and Subject Index (1998) (0)
- Preface: Lars Gustafson, Lund; Arne Brun, Lund (1999) (0)
- 9 Caged rucaparib: cancer directed delivery of PARPi (2022) (0)
- A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers (2019) (0)
- Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. (2022) (0)
- Synthetic lethality as an engine for cancer drug target discovery (2019) (0)
- Is there a link between schizophrenia and mutations at the fragile-X gene, FMR-1? (1993) (0)
- A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo (2023) (0)
- Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking (2020) (0)
- PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors. (2022) (0)
- Abstract 299: Large tandem duplications in cancer resulting from transcription and DNA replication collisions (2023) (0)
- Childhood body size and pubertal timing in relation to adult mammographic density phenotype (2017) (0)
- TEAD Proteins Associate With DNA Repair Proteins to Facilitate Cellular Recovery From DNA Damage (2023) (0)
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (0)
- Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology (2023) (0)
- RASA2 ablation in T cells boosts antigen sensitivity and long-term function (2022) (0)
- JAK2 Is a Direct BCL6 Target Gene: Implications for Therapy in Diffuse Large B-Cell Lymphoma (2014) (0)
- Abstract 3417: An in vivo functional screen to identify metastasis suppressor genes (2012) (0)
- Abstract 3039: Identification of a novel biomarker of resistance to lapatinib common to both breast and oesophagogastric cancer (2011) (0)
- expressing are for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. (2010) (0)
- A method for resequencing from minimal amounts of starting DNA. (2012) (0)
- sense Variants in ATM in 26 , 101 Breast Cancer B & P es and 29 , 842 Controls (2010) (0)
- Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study (2018) (0)
- IN CONFIDENCE Full title : Familial concordance for age at natural menopause : results from the Breakthrough Generations Study Running title : Familial concordance for age at menopause (2011) (0)
- 146 Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells (2016) (0)
- Hyperplastic/proliferating perilobar nephrogenic rests are molecular genetic precursor lesions of Wilms tumor (2007) (0)
- Hypoxia is a dominant remodeler of the CD8+ T cell surface proteome relative to activation and regulatory T cell-mediated suppression (2021) (0)
- Correction: Lkb1 Deficiency Alters Goblet and Paneth Cell Differentiation in the Small Intestine (2019) (0)
- The Structure of the Cyld Usp Domain Explains its Specificity for Lys63-Linked Polyubiquitin and Reveals a B-Box Module (2008) (0)
- Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study (2014) (0)
- Abstract #3601: A pharmacodynamic (PD) evaluation of the PARP inhibitor olaparib (AZD2281) in a first-in-human Phase I trial of patients with advanced solid tumours (2009) (0)
- Abstract P3-08-04: Impact of CYP3A variation on estrone levels and breast cancer risk (2012) (0)
- 1 Harnessing Genetic Dependencies In Cancer Therapy (2012) (0)
- Authors and Disclosures (2010) (0)
- 186 INVITED Synthetic lethal approaches as potential therapies for tumours deficient in DNA repair pathways (2007) (0)
- Molecular and Cellular Pathobiology 19 p 13 . 1 Is a Triple-Negative – Speci fi c Breast Cancer Susceptibility Locus (2012) (0)
- Abstract AACR1-1: Synthetic Lethal Approaches to Cancer Therapy (2010) (0)
- Abstract 2931: Cancer cells deficient in DNA mismatch repair (MMR) are selectively sensitive to inhibition of the DNA dependent protein kinase (DNA-PK) (2014) (0)
- Abstract A09: Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors (2013) (0)
- Treatment with the PARP inhibitor olaparib in a patient with PTEN-deficient endometrial cancer (2011) (0)
- IDENTIFICATION OF NOVEL FUSION GENES IN PAEDIATRIC HIGH GRADE GLIOMA (2012) (0)
- Molecular alterations of PDGA and PDGFRA in Gliomas (2009) (0)
- Dysregulated tropomyosin receptor kinase (Trk) signalling in CYLD mutant tumours (2010) (0)
- Abstract 4829: Massively parallel RNA sequencing analysis of micropapillary carcinomas of the breast (2011) (0)
- 318 Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC) (2014) (0)
- Candidate drug therapies for molecularly defined subgroups of esophageal cancer identified from high-throughput drug screening. (2014) (0)
- Response to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study” (2018) (0)
- A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations (2010) (0)
- 288 Synthetic Lethality in ERCC1-deficient Non-Small Cell Lung Cancer (2012) (0)
- Abstract 3917: EMSY amplification and overexpression is not associated with defective homologous recombination and does not predict sensitivity to cisplatin or PARP inhibitors (2011) (0)
- Abstract IA23: Harnessing genetic dependencies in cancer therapy (2011) (0)
- The Breast Cancer Susceptibility Genes BRCA1 and BRCA2 (2002) (0)
- The Tcp-1-related gene, Cctg, maps to mouse Chromosome 3 (1994) (0)
- Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells (2009) (0)
- Prevention and Epidemiology Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk (2012) (0)
- Abstract P1-04-01: Epigenome-wide association study for breast cancer risk using whole genome and target captured bisulphite sequencing: A pooled case-control study nested in the breakthrough generations study (2017) (0)
- Estrogen receptor positive luminal progenitors the cancer cell origin for Estrogen receptor positive breast cancer (2019) (0)
- Upregulation of MYCN Histone H 3 . 3 Mutations Drive Pediatric Glioblastoma through (2013) (0)
- Abstract 2975: Synthetic lethality in synovial sarcoma: SS18-SSX fusions and DNA damage response (DDR) inhibitors (2018) (0)
- Abstract 1360: A PARylation biosensor genetic screen to identify novel PARylation targets (2018) (0)
- Differential gene expression patterns in lymphoblastoid cell lines from patients heterozygous for BRCA1 and BRCA2 germline mutations (2003) (0)
- Comparative molecular pathology of adenoid cystic carcinoma from different sites: A microarray-based CGH analysi (2007) (0)
- 42OProfiles of genome complexity identify HORMAD1 as a driver of homologous recombination deficiency and platinum therapy response in triple-negative breast cancer (2015) (0)
- Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance (2018) (0)
- H3F3A MUTATIONS IN PAEDIATRIC GLIOBLASTOMA REGULATE A SELF-RENEWAL GENE SIGNATURE (2012) (0)
- Abstract 5082: Whole-exome sequencing of an adult pituitary atypical teratoid rhabdoid tumor (AT/RT) - A not so simple genome as pediatric AT/RT (2014) (0)
- Mapping of two zinc finger protein genes to mouse Chromosomes 4 and 7 (1995) (0)
- NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear-mitochondrial crosstalk in ERCC1-deficient populations. (2017) (0)
- MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors. (2010) (0)
- Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
- A Novel Tumour-Based Test To Identify Breast Cancer Due to BRCA1 and BRCA2 Mutations. (2009) (0)
- Genomic Complexity Profi ling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Defi ciency in Triple-Negative Breast Cancers (2015) (0)
- Abstract 2308: The protein interaction landscape of breast cancer (2021) (0)
- Comparative molecular pathology of adenoid cystic carcinoma from different sites: A microarray-based CGH analysis (2007) (0)
- Abstract 783: Epigenomic detection of multiple cancers in plasma derived cell free DNA (2020) (0)
- Changes in DNA hydroxymethylation for the detection of multiple cancers in plasma cell-free DNA. (2019) (0)
- Loss of organisation in CYLD defective tumours is associated with diminished DKK2 expression. (2013) (0)
- 201 Targeting tropomyosin receptor kinase (TRK) in CYLD defective tumours: A placebo-controlled early phase trial with pegcantratinib (2017) (0)
- Abstracts of papers presented at the second Mammalian Genetics and Development Workshop held in the Linnean Society Rooms, Burlington House, Piccadilly, London on 5–7 November 1991 (2008) (0)
- Phillips Structure and expression of genes coding for components of the cytochrome P-450-mediated mono-ox ygenase (2009) (0)
- Edinburgh Research Explorer Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer (2018) (0)
- Smoking and risk of breast cancer in the Generations Study cohort (2017) (0)
- Effect of detection of epigenomic changes in plasma-derived cell-free DNA on multicancer classification. (2020) (0)
- Abstract P5-14-03: Withdrawn (2018) (0)
- Abstract B28: Screening for kinase dependencies in HPV-associated cancer (2013) (0)
- Inhibitors of DNA damage repair for the treatment of cancer. (2004) (0)
- Exome Sequencing of the t(4;14) and t(11;14) Translocation Specific Subgroups of MM (2011) (0)
- Abstract 410: Genome-wide and focused CRISPR screens to study PARP inhibitor resistance mediated by mutations inPARP1 (2018) (0)
- Targeting BRCAness in Gastric Cancer (2017) (0)
- MicroArrays comparative genomic hybridisation (aCGH) and response to neoadjuvant chemotherapy (CT) in breast cancer (BC) (2005) (0)
- Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice. (2012) (0)
- 137 Haploid Genetic Screens to Identify Determinants of Drug Toxicity and Resistance (2012) (0)
- susceptibility loci by Capture HiC Unbiased analysis of potential targets of breast cancer (2014) (0)
- Synthetic lethal approaches to the treatment of cancers with DNA repair defects (2007) (0)
- Differential cell surface protein expression in response to PARP inhibition in mutant isogenic ovarian and breast cancer cells using a novel proteomic technique (2019) (0)
- 88 Genome-wide drug sensitivity screens in haploid mouse embryonic stem cells (2014) (0)
- Reply to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study” (2018) (0)
- Isolation and sequence of a human cytochrome P-450 cDNA clone ( recombinant DNA / DNA sequence / amino acid sequence / monooxygenase / Southern blot analysis ) (2003) (0)
- Abstract 4987: Identification of novel genes and pathways involved in resistance to HER2-targeting agents in breast cancer (2011) (0)
- Abstract PR08: Discovery of immune regulators in primary human T cells using genome-wide CRISPR screens (2020) (0)
- Identification and characterisation of novel associations in the CASP 8 / ALS 2 CR 12 region 1 on chromosome 2 with breast cancer risk 2 3 (2014) (0)
- Do Chromosome 17 Centromere Copy Numbers Predict Polysomy? A Fluorescence In Situ Hybridization and Microarray-Based CGH Analysis. (2009) (0)
This paper list is powered by the following services:
Other Resources About Alan Ashworth
What Schools Are Affiliated With Alan Ashworth?
Alan Ashworth is affiliated with the following schools:
